

Haematologica
HAEMATOL/2019/244020
Version 3

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis, Antonio Cavazos, Vinitha Mary Kuruvilla, Jayant Raman, Vidhi Mody, Edna F. Choo, Monique Dail, Neil P. Shah, Marina Konopleva, Deepak Sampath, and Elisabeth A. Lasater

Disclosures: Venetoclax is developed in collaboration between Genentech, Inc. and AbbVie. R.S.M., V.M., E.F.C., M.D., D.S. and E.A.L. are current or former employees of Genentech, Inc.. N.P.S.: Research funding from Bristol-Myers Squibb. M.K.: Consultant for AbbVie, Genentech, F. Hoffman La-Roche; served as advisory board member for F. Hoffman La-Roche and AbbVie; holds shares from Reata Pharmaceuticals; honoraria from Amgen, Abbvie, Genentech; research funding from AbbVie, Genentech, Eli Lilly, Cellectis, Calithera, Stemline, Threshold, Flexus Biosciences, Novartis, Ablynx, Agios and Amgen. All other authors declare no conflicts of interest. The current affiliation of D.S. is Ultragenyx Pharmaceutical

Contributions: R.S.M., Q.Z., R.D., E.F.C., M.D., N.P.S., M.K., D.S. and E.A.L. designed experiments and analyzed data. R.S.M., E.A.L., Q.Z., R.D., V.M.K., A.C., V.M. and J.R. performed experiments. R.S.M., M.D., D.S. and E.A.L. wrote the manuscript. All authors reviewed and edited the manuscript.